Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Andreas Mitsch"'
Publikováno v:
Cancer Research. 80:5585-5585
Novel anti-cancer immune therapeutic strategies, like various new antibody formats and/or tumor vaccines, show promising results in patients. However, due to the “immune-escape phenomenon” driven by tumor-secreted Transforming Growth Factor-beta
Autor:
Dariush Moahammad Soleymani, Mohammad Reza Gholami, Giovanni Del Galdo, Jens Mueckenheim, Andreas Mitschele-Thiel
Publikováno v:
EURASIP Journal on Wireless Communications and Networking, Vol 2022, Iss 1, Pp 1-29 (2022)
Abstract Capacity, reliability, and latency are seen as key requirements of new emerging applications, namely vehicle-to-everything (V2X) and machine-type communication in future cellular networks. D2D communication is envisaged to be the enabler to
Externí odkaz:
https://doaj.org/article/a59f1f9094864a859cfaa5de7ab67d26
Publikováno v:
Archiv der Pharmazie. 338:9-17
We recently described two novel aryl binding sites of farnesyltransferase. The 4- and 5-arylsubstituted thienylacryloyl moieties turned out as appropriate substituents for our benzophenone-based AAX-peptidomimetic capable for occupying the far aryl b
Publikováno v:
Archiv der Pharmazie. 336:242-250
Some 5-acylaminoacylamino-benzophenone derivatives were designed as bisubstrate analogue farnesyltransferase inhibitors. These compounds turned out to be only weakly active against farnesyltransferase, but displayed an antiproliferative effect render
Publikováno v:
Bioorganic & Medicinal Chemistry. 10:2657-2662
We recently described a novel aryl binding site of farnesyltransferase. The 2-naphthylacryloyl residue was developed as an appropriate substituent for our benzophenone-based AAX-peptidomimetic capable of occupying this binding site, resulting in a no
Publikováno v:
Archiv der Pharmazie. 334:40-44
We describe a novel class of benzophenone-based farnesyltransferase inhibitors exploiting a novel aryl binding region in the farnesyltransferase's active site. The present study was mainly focussed on structural modifications of the trimethylene spac
Publikováno v:
ChemInform. 32
Publikováno v:
Cancer Research. 75:301-301
Novel anti-cancer immune therapeutic strategies, like various new antibody formats and/or tumor vaccines, show promising results in patients. However, due to the “immune-escape phenomenon” driven by tumor-secreted Transforming Growth Factor-beta
Autor:
Andreas Mitsch, Pia Wißner, Markus Böhm, Katrin Silber, Gerhard Klebe, Isabel Sattler, Martin Schlitzer
Publikováno v:
Archiv der Pharmazie. 337(9)
We recently described two novel aryl binding sites of farnesyltransferase. In this study, the cinnamoyl residue was designed as an appropriate substituent for our benzophenone-based AAX-peptidomimetic compound capable of occupying the far aryl bindin
Autor:
Peter W. Haebel, Gerhard Klebe, Isabel Sattler, Katrin Silber, Martin Schlitzer, Pia Wissner, Andreas Mitsch
Publikováno v:
Bioorganicmedicinal chemistry. 12(17)
We have designed arylfurylacryl-substituted benzophenones as non-thiol farnesyltransferase inhibitors utilizing a novel aryl binding site of farnesyltransferase. These compounds display activity in the low nanomolar range.